Lupin is planning to raise around Rs 7,500 crore through various instruments either in domestic or overseas market or both. An enabling resolution seeking shareholders' nod for the fund-raising move will be placed at the forthcoming AGM next month.
The company’s board at its meeting on June 22 gave its approval in principle for raising of funds up to Rs 7500 crore by way of issue of securities i.e., equity shares, GDRs, ADRs, convertible bonds, equity linked instruments, etc. as may be appropriate. The enabling approval of the shareholders will be sought at the AGM to be held on July 23.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1905.00 |
| Dr. Reddys Labs. | 1370.35 |
| Cipla | 1457.05 |
| Zydus Lifesciences | 1139.60 |
| Lupin | 2479.95 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: